Effects of metaproterenol on pulmonary mechanics, oxygenation, and ventilation in infants with chronic lung disease.
Changes in pulmonary resistance, dynamic compliance, tidal volume, and transcutaneous PO2 and PCO2 after nebulized administration of metaproterenol were evaluated in eight newborn infants (birth weight 650 to 1060 g, gestational age 25 to 28 weeks) with chronic lung disease receiving mechanical ventilation. The infants were monitored continuously before and for 15 minutes after nebulization of metaproterenol during 3 consecutive days at mean age 34 days. There were significant increases in compliance, tidal volume, and tcPO2, and significant decreases in pulmonary resistance and tcPCO2. These data show that bronchospasm contributes significantly to the high pulmonary resistance in preterm infants with chronic lung disease and that metaproterenol is beneficial in the therapy of infants with chronic lung disease requiring mechanical ventilation.
D001785:Blood Gas Monitoring, Transcutaneous; D002908:Chronic Disease; D003131:Combined Modality Therapy; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008168:Lung / Q000187:drug effects* / Q000503:physiopathology; D008171:Lung Diseases / Q000188:drug therapy* / Q000503:physiopathology / Q000628:therapy; D009921:Metaproterenol / Q000627:therapeutic use*; D009330:Nebulizers and Vaporizers; D012119:Respiration / Q000187:drug effects*; D012121:Respiration, Artificial; D012129:Respiratory Function Tests
D009921:Metaproterenol